Coherus Oncology, Inc.
Coherus Oncology, Inc.（CHRS）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
chrs · 股价预测 · 16 位分析师（近3月）· FMP · 更新于 2026年6月8日
分析师评级与共识
基于过去 3 个月内 16 位华尔街分析师
Buy
16 位分析师
共识
评级分布
12 个月目标价
High
$11.00
Consensus
$6.02
+323.9% upside
Low
$1.05
Median: $6 · Last Close: $1.42
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
Consensus Target
$6.02
323.9% upside
High Target
$11
674.6%
Low Target
$1.05
-26.1%
Current Price
$1.42
as of today
Based on analyst price targets, the CHRS stock price prediction for the next 12 months ranges from $1.05 to $11. The consensus CHRS price forecast of $6.02 implies 323.9% upside from the current price of $1.42.
短期股价预测
Low Activity算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $1.37 | ↓ 3.75% |
1-day model range: $1.34–$1.4. Peak: $1.4 (-3.75%).
长期股价预测
年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | — | -50.0% |
| 2028 | — | -62.5% |
| 2029 | — | -67.2% |
| 2030 | — | -69.2% |
| 2031 | — | -70.2% |
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · CHRS · Jun 8, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-09-04 | Maxim Group | Upgrade ↑ | Hold→Buy |
| 2025-04-29 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-04-24 | UBS | Maintains | Neutral→Neutral |
| 2025-03-11 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-01-23 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-01-22 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-12-05 | Baird | Maintains | Outperform→Outperform |
| 2024-12-04 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-11-08 | Baird | Maintains | Outperform→Outperform |
| 2024-11-07 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Coherus Oncology, Inc. (CHRS) stock. Of the recent 81 rating actions, 2 were upgrades and 3 were downgrades. 16 analysts currently cover CHRS.
分析师推荐趋势
CHRS analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$73M
↓ 60.5% YoY
Revenue Next Year
$88M
↑ 21.1% YoY
EPS This Year
$-1.01
EPS Next Year
$-0.64
↓ 37.1% YoY
EPS ForecastReported vs Estimated
Analysts forecast CHRS EPS of $-1.01 for the current fiscal year, based on estimates from 2 analysts. The CHRS revenue forecast is $73M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
CHRS 股价预测由两类独立数据源支撑：来自 16 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。CHRS 的共识目标价为 $6.02（+323.9% 上行空间），分析师共识为 Buy。
CHRS 的短期预测（明日）为 $1.37（-3.75%）。 CHRS 对 2030 年的预测区间为 $0–$0。
Coherus Oncology, Inc. 在 NASDAQ 上市，代码 CHRS。CHRS 在 2027 年的整体展望偏积极，在覆盖分析师中约 81% 对应 Buy 共识。
常见问题
CHRS 预测 · 8 个问题根据 16 位华尔街分析师，CHRS 的 12 个月平均目标价为 $6.02，最高 $11.00、最低 $1.05。若有图表，中位目标价可在上方查看。相对当前价 $1.42，隐含约 +323.9% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.